報價延遲最少15分鐘:2026/04/18 11:34 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1788 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.22/0.54
|
|
企業價值
35.78M
|
| 資產負債 |
|
每股賬面淨值
-0.22
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.73M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring. |
